Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTAS: Apalutamide With Continued vs Intermittent ADT in mCSPC
NCT05884398Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 3 trial of apalutamide in prostate cancer (PCa), sponsored by Janssen Pharmaceutical. Started Aug 2023; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05884398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884398.